Carvedilol
Carvedilol Orion belongs to a group of medicines called beta-blockers, which have a relaxing and vasodilating effect, making it easier for the heart to pump blood into the body and lowering blood pressure and reducing the resistance that the heart has to overcome when pumping blood.
If any of the above situations apply to the patient, they should not take Carvedilol Orion.
Before starting to take Carvedilol Orion, the patient should discuss it with their doctor or pharmacist
The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or might take.
The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or might take, including those bought without a prescription or herbal products. It is especially important to inform the doctor if the patient is currently being treated with any of the following medicines:
Before surgery, the patient should tell their doctor that they are taking Carvedilol Orion.
Carvedilol Orion should be taken with a glass of water.
If the patient is taking Carvedilol Orion for heart failure, they should take it with a glass of water during meals (see section 3: "How to take Carvedilol Orion").
The patient should avoid drinking grapefruit juice at the same time as or shortly after taking Carvedilol Orion.
Grapefruit or its juice may increase the levels of the active substance carvedilol in the blood and cause unpredictable increases in the frequency of side effects.
The patient should not drink alcohol while taking Carvedilol Orion, as it may increase the effects of alcohol.
The patient should not takethis medicine without first consulting their doctor if they are pregnant or breastfeeding.
The patient should contact their doctor immediately if they become pregnant while taking this medicine.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
While taking Carvedilol Orion, the patient may experience dizziness or fatigue.
This is most likely to happen at the start of treatment or when the dose is changed.
In such cases, the patient should not drive or operate machinery.
The patient should avoid drinking alcohol, as it may worsen these symptoms.
If the patient is unsure or wants more information, they should talk to their doctor.
Carvedilol Orioncontains lactose and sucrose (certain types of sugars). If the patient has been told that they have an intolerance to some sugars, they should contact their doctor before taking the medicine.
This medicine should always be taken exactly as prescribed by the doctor. If the patient is unsure, they should consult their doctor or pharmacist.
Carvedilol Orion should be swallowed with a glass of water.
Adults:The usual starting dose is 12.5 mg once daily for the first two days, and then 25 mg once daily. If necessary, the doctor may increase the dose gradually at intervals of at least two weeks. The recommended maximum daily dose is 50 mg (the recommended maximum single dose is 25 mg).
Elderly patients:The doctor will usually prescribe a starting dose of 12.5 mg once daily and will continue treatment at an unchanged level for the entire treatment period. If necessary, the doctor may increase the dose gradually at intervals of at least two weeks.
Adults:The usual starting dose is 12.5 mg twice daily for the first two days, and then 25 mg twice daily. If necessary, the doctor may increase the dose gradually at intervals of at least two weeks to a maximum dose of 100 mg daily in two divided doses.
Elderly patients:The recommended starting dose is 12.5 mg twice daily for the first two days, and then 25 mg twice daily, which is the recommended maximum daily dose.
Adults and elderly patients:In the treatment of stable heart failure, the tablets should be taken twice daily, in the morning and evening. The tablets should be taken with food to reduce the risk of side effects.
The starting dose is 3.125 mg twice daily for two weeks. The doctor may increase the dose gradually at intervals of at least two weeks to determine the optimal dose for the patient.
If the patient weighs less than 85 kg, the recommended maximum dose of Carvedilol Orion is 25 mg twice daily, and if the patient weighs more than 85 kg, the doctor may increase the dose to 50 mg twice daily.
In the treatment of heart failure, it is recommended that treatment with Carvedilol Orion be initiated and monitored by a hospital doctor with experience in the treatment of heart failure.
If the patient has stopped taking Carvedilol Orion for more than two weeks, they will need to restart with the starting dose and gradually increase it again.
Sometimes, heart failure may worsen while taking Carvedilol Orion, especially at the start of treatment. This may worsen subjective symptoms (e.g., fatigue, difficulty breathing) and objective symptoms of fluid retention (e.g., weight gain and swelling of the legs).
If the patient experiences such symptoms or their condition worsens while taking Carvedilol Orion, they should inform their doctor, as this may require a change in the dose of other medicines or Carvedilol Orion.
While taking Carvedilol Orion, the patient should ensure that they are taking their other heart failure medicines as prescribed by their doctor.
Depending on the patient's condition, the doctor may reduce the dose compared to the recommended dose above.
Carvedilol Orion is not intended for use in this age group.
In case of accidental ingestion of more than the recommended amount of tablets, the patient should immediately contact their doctor or go to the nearest hospital emergency department. Dizziness, nausea, fainting, shortness of breath, or difficulty breathing, bradycardia, the patient may be very sleepy or have seizures.
If the patient forgets to take a dose, they should not worry. The missed dose should be taken as soon as they remember. However, if it is almost time for the next dose, the missed dose should be skipped. The next dose that the patient would normally take should be taken at the usual time. The patient should not take a double dose to make up for the missed dose.
The patient should not stop taking Carvedilol Orion suddenly without consulting their doctor.
In case of sudden discontinuation of treatment, side effects may occur. The doctor will advise how to gradually reduce the dose to stop treatment. If the patient is taking a medicine called clonidine, they should never stop treatment with either of these medicines without consulting their doctor.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Carvedilol Orion can cause side effects, although not everybody gets them.
Most side effects are dose-dependent and will disappear after the dose is reduced or treatment is stopped. Some side effects may occur at the start of treatment and will disappear spontaneously during continued treatment.
Carvedilol may also cause bradycardia (a heart disease that causes very slow heartbeats or cardiac arrest) in predisposed patients (e.g., elderly patients or patients with pre-existing slow heart rate [bradycardia], sinoatrial node dysfunction, or heart conduction disorders [atrioventricular block]).
dizziness,
headache,
fatigue,
low blood pressure,
heart failure.
bronchitis, pneumonia, upper respiratory tract infections,
urinary tract infections,
low red blood cell count,
weight gain,
increased cholesterol levels,
loss of control of blood sugar levels in people with diabetes,
depression, sadness,
vision disturbances,
reduced tear production, eye irritation,
slow heart rate,
swelling (generalized swelling of the body, swelling of body parts), fluid overload, increased blood volume in the body,
dizziness when standing up quickly,
circulation problems (including cold hands and feet), arteriosclerosis (hardening of the arteries), worsening of symptoms in patients with Raynaud's syndrome (successive blanching, cyanosis, and redness of fingers and toes, accompanied by pain) and intermittent claudication (pain in the legs that worsens during walking),
high blood pressure,
asthma and breathing difficulties,
fluid accumulation in the lungs,
diarrhea,
malaise, nausea, vomiting, abdominal pain, indigestion,
pain (e.g., in the arms and legs),
severe kidney failure and kidney function disorders in patients with arteriosclerosis and/or kidney function disorders,
urination difficulties.
sleep disturbances,
nightmares,
hallucinations,
confusion,
fainting,
abnormal sensations,
heart conduction disorders, angina pectoris (including chest pain),
certain types of skin reactions (e.g., allergic dermatitis, urticaria, itching, and skin rash, increased sweating, psoriatic or lichenoid skin changes),
hair loss,
impotence,
constipation.
low platelet count (thrombocytopenia),
dry mouth,
nasal congestion (feeling of nasal stuffiness).
low white blood cell count,
allergic reactions,
psychosis,
changes in liver function test results,
difficulty controlling the bladder when urinating in women (urinary incontinence),
skin rash that may cause blisters and looks like small targets (erythema multiforme),
widespread rash with blisters and peeling skin, mainly on the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome),
a more severe form causing widespread skin peeling (affecting more than 30% of the body surface – toxic epidermal necrolysis).
If the patient experiences any side effects, including any possible side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, the patient can help provide more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The patient should not use this medicine after the expiry date stated on the label after EXP:. The expiry date refers to the last day of the month stated.
The medicine should not be stored above 30°C.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Coated tablet
Carvedilol Orion 6.25 mg, coated tablets:
White or almost white coated tablets, oval, marked with the symbol "F57" on one side and a score line on the other side. The tablet can be divided into equal doses.
Carvedilol Orion 12.5 mg, coated tablets:
White or almost white coated tablets, oval, marked with the symbol "F58" on one side and a score line on the other side. The tablet can be divided into equal doses.
Carvedilol Orion 25 mg, coated tablets:
White or almost white coated tablets, oval, marked with the symbol "F59" on one side and a score line on the other side. The tablet can be divided into equal doses.
Blister:
Pack sizes: 30 and 100 coated tablets.
HDPE bottle:
Pack sizes: 30 and 100 coated tablets.
Not all pack sizes may be marketed.
Orion Corporation
Orionintie 1
02200 Espoo
Finland
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Orion Corporation,
Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland
To obtain more detailed information on this medicine, the patient should contact the local representative of the marketing authorization holder:
Orion Pharma Poland Sp. z o.o.
kontakt@orionpharma.info.pl
Denmark
Carvedilol "Aurobindo"
Finland
Carvedilol Orion 6.25 mg/12.5 mg/25 mg tablets, coated
Spain
Carvedilol Aurobindo 6.25 mg film-coated tablets
Germany
Carvedilol Aurobindo 3.125 mg/6.25 mg/12.5 mg/25 mg film-coated tablets
Malta
Carvedilol 3.125 mg/6.25 mg/12.5 mg/25 mg film-coated tablets
Poland
Carvedilol Orion
Norway
Carvedilol Aurobindo 6.25 mg/12.5 mg/25 mg tablets, film-coated
Sweden
Carvedilol Aurobindo 6.25 mg/12.5 mg/25 mg film-coated tablets
Date of last revision of the leaflet:10.02.2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.